11th Neurodegenerative Drug Development Summit

The 11th Neurodegenerative Drug Development Summit is dedicated to argeting neurodegenerative diseases and challenging traditional thinking around disease aetiology.

Key Topics

• Shortcomings in preclinical models to confidently translate into clinical development
• Biological understanding of neurodegeneration and awareness of emerging targets for more promising target identification and selection
• Digital developments for their successful integration into clinical settings for earlier diagnosis
• Neurodegenerative biomarker advances that will improve scale sensitivity and clinical practicality for monitoring disease progression
• Pharmaceutical investment strategies and business models to financially de- risk neurodegenerative drug development
• Clinical trial design for homogeneous, rapidly progressing patient populations allowing for shorter, less expensive trials with more immediate benefit to patients and attractiveness to payers
• Genetic profiling of patients to manage clinical heterogeneity for patient stratification

Who should Attend

Consortia, leading scientists and pharmaceutical business leaders.